Exclusive Summary

• Backed by US-FDA and PIC/S GMP certifications, ensuring rapid regulatory approval and seamless market penetration across stringent global markets.
• Serves as a guideline-recommended first-line therapy for endometriosis, addressing a massive global market of approximately 190 million reproductive-age women needing chronic care.
• Offers lucrative profit margins for distribution partners by providing a highly cost-effective generic alternative capitalizing on the originator's broad patent expiry.
• Provides a strong competitive edge and supply chain resilience due to the strict manufacturing barriers globally associated with dedicated hormonal production facilities.